212 related articles for article (PubMed ID: 16115911)
1. Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype.
Chapman EJ; Harnden P; Chambers P; Johnston C; Knowles MA
Clin Cancer Res; 2005 Aug; 11(16):5740-7. PubMed ID: 16115911
[TBL] [Abstract][Full Text] [Related]
2. CDKN2A gene inactivation in epithelial sporadic ovarian cancer.
Niederacher D; Yan HY; An HX; Bender HG; Beckmann MW
Br J Cancer; 1999 Aug; 80(12):1920-6. PubMed ID: 10471040
[TBL] [Abstract][Full Text] [Related]
3. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development.
Pollock PM; Welch J; Hayward NK
Cancer Res; 2001 Feb; 61(3):1154-61. PubMed ID: 11221846
[TBL] [Abstract][Full Text] [Related]
4. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
[TBL] [Abstract][Full Text] [Related]
5. Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR.
Berggren P; Kumar R; Sakano S; Hemminki L; Wada T; Steineck G; Adolfsson J; Larsson P; Norming U; Wijkström H; Hemminki K
Clin Cancer Res; 2003 Jan; 9(1):235-42. PubMed ID: 12538475
[TBL] [Abstract][Full Text] [Related]
6. Patterns of CDKN2A gene loss in sequential oral epithelial dysplasias and carcinomas.
Shahnavaz SA; Bradley G; Regezi JA; Thakker N; Gao L; Hogg D; Jordan RC
Cancer Res; 2001 Mar; 61(6):2371-5. PubMed ID: 11289098
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of homozygous deletions and multiple duplications at the CDKN2A (p16INK4a)/ARF (p14ARF) locus in urinary bladder cancer.
Berggren de Verdier PJ; Kumar R; Adolfsson J; Larsson P; Norming U; Onelöv E; Wijkström H; Steineck G; Hemminki K
Scand J Urol Nephrol; 2006; 40(5):363-9. PubMed ID: 17060081
[TBL] [Abstract][Full Text] [Related]
8. Preferential loss of expression of p16(INK4a) rather than p19(ARF) in breast cancer.
Brenner AJ; Paladugu A; Wang H; Olopade OI; Dreyling MH; Aldaz CM
Clin Cancer Res; 1996 Dec; 2(12):1993-8. PubMed ID: 9816158
[TBL] [Abstract][Full Text] [Related]
9. 5' cytosine-phospho-guanine island methylation is responsible for p14ARF inactivation and inversely correlates with p53 overexpression in resected non-small cell lung cancer.
Hsu HS; Wang YC; Tseng RC; Chang JW; Chen JT; Shih CM; Chen CY; Wang YC
Clin Cancer Res; 2004 Jul; 10(14):4734-41. PubMed ID: 15269146
[TBL] [Abstract][Full Text] [Related]
10. High frequency of p16INK4A gene alterations in hepatocellular carcinoma.
Liew CT; Li HM; Lo KW; Leow CK; Chan JY; Hin LY; Lau WY; Lai PB; Lim BK; Huang J; Leung WT; Wu S; Lee JC
Oncogene; 1999 Jan; 18(3):789-95. PubMed ID: 9989830
[TBL] [Abstract][Full Text] [Related]
11. Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma.
Thompson PM; Maris JM; Hogarty MD; Seeger RC; Reynolds CP; Brodeur GM; White PS
Cancer Res; 2001 Jan; 61(2):679-86. PubMed ID: 11212268
[TBL] [Abstract][Full Text] [Related]
12. Early acquisition of homozygous deletions of p16/p19 during squamous cell carcinogenesis and genetic mosaicism in bladder cancer.
Tsutsumi M; Tsai YC; Gonzalgo ML; Nichols PW; Jones PA
Oncogene; 1998 Dec; 17(23):3021-7. PubMed ID: 9881704
[TBL] [Abstract][Full Text] [Related]
13. p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma.
Fujimoto A; Morita R; Hatta N; Takehara K; Takata M
Oncogene; 1999 Apr; 18(15):2527-32. PubMed ID: 10229204
[TBL] [Abstract][Full Text] [Related]
14. CDKN2A/p16 is inactivated in most melanoma cell lines.
Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis.
Kawaguchi K; Oda Y; Saito T; Yamamoto H; Tamiya S; Takahira T; Miyajima K; Iwamoto Y; Tsuneyoshi M
J Pathol; 2003 Nov; 201(3):487-95. PubMed ID: 14595762
[TBL] [Abstract][Full Text] [Related]
16. DNA studies underestimate the major role of CDKN2A inactivation in oral and oropharyngeal squamous cell carcinomas.
Wu CL; Roz L; McKown S; Sloan P; Read AP; Holland S; Porter S; Scully C; Paterson I; Tavassoli M; Thakker N
Genes Chromosomes Cancer; 1999 May; 25(1):16-25. PubMed ID: 10221335
[TBL] [Abstract][Full Text] [Related]
17. Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population.
Biden K; Young J; Buttenshaw R; Searle J; Cooksley G; Xu DB; Leggett B
Hepatology; 1997 Mar; 25(3):593-7. PubMed ID: 9049204
[TBL] [Abstract][Full Text] [Related]
18. Molecular evidence supporting field effect in urothelial carcinogenesis.
Jones TD; Wang M; Eble JN; MacLennan GT; Lopez-Beltran A; Zhang S; Cocco A; Cheng L
Clin Cancer Res; 2005 Sep; 11(18):6512-9. PubMed ID: 16166427
[TBL] [Abstract][Full Text] [Related]
19. [Relationship between alterations of p16INK4a and p14ARF genes of CDKN2A locus and gastric carcinogenesis].
Tang SH; Yang DH; Luo HS; Yu JP; Shu JC
Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):517-21. PubMed ID: 15231134
[TBL] [Abstract][Full Text] [Related]
20. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]